Novartis Takes On Colombia Over Glivec Pricing

Novartis is taking Colombian authorities to court over moves to cut the price of its anticancer Glivec (imatinib) and warns that the intellectual property rights of other products are under threat. Companies selling hepatitis C drugs should pay attention as their products could be next to face similar measures.

Novartis AG is fighting what it thinks are unfair tactics by the Colombian health ministry to undermine intellectual property rights and cut the price of its anticancer Glivec (imatinib). It claims it is taking action to stop the same thing happening to other pharmaceuticals. Indeed, pressure is mounting from civil society to make hepatitis C treatments, including Gilead Sciences Inc.’s Sovaldi (sofosbuvir), Bristol-Myers Squibb Co.'s Daklinza (daclatasvir) and Merck & Co. Inc.‘s Victrelis (boceprevir) more accessible.

In the latest development in the wrangling over Glivec, the Colombian health ministry has announced the national pricing commission’s decision...

More from Business

More from Scrip

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.